In March 2025, the company declared new designs for any immediate-to-purchaser offering of its Wegovy weight loss drug. The company founded a new pharmacy, referred to as NovoCare, which would charge customers $499 each month for access to the drug, a lot less than 50 % the expense of the drug by means of other pharmaceutical distribution networks.